Koss Olinger Consulting LLC Buys 18,298 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Koss Olinger Consulting LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 115.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,168 shares of the company’s stock after acquiring an additional 18,298 shares during the quarter. Koss Olinger Consulting LLC’s holdings in CRISPR Therapeutics were worth $1,345,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics during the third quarter valued at $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the third quarter valued at $43,000. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at $39,000. Western Pacific Wealth Management LP lifted its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Finally, Spire Wealth Management lifted its position in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CRSP shares. Bank of America lowered their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. JMP Securities restated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Price Performance

CRSP stock opened at $40.97 on Wednesday. The company has a market capitalization of $3.51 billion, a PE ratio of -9.38 and a beta of 1.76. The firm’s 50-day moving average is $43.04 and its 200 day moving average is $45.47. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now directly owns 7,000 shares in the company, valued at approximately $313,950. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,381 shares of company stock valued at $1,608,243. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.